Bioreductive drugs: from concept to clinic.
Clinical oncology (Royal College of Radiologists (Great Britain)) • Vol. 19, Issue 6 • 2007
Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.
Rapid communications in mass spectrometry : RCM • Vol. 21, Issue 7 • 2007
Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 13, Issue 7 • 2007
A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
The journal of gene medicine • Vol. 7, Issue 7 • 2005